to support Company’ Innovation Capabilities
Lyon, France – June 15, 2023 – ErVaccine Technologies, a French biotechnology company developing next-generation therapeutic vaccines and cellular immunotherapies in oncology, targeting new families of « unconventional » tumor antigens derived from human endogenous retroviruses (HERVs), announced today the renewing of the Bioinformatics team by appointing talented people skilled in computational biology and machine learning.